Komboglyze

Metformin Hydrochloride and Saxagliptin, the active ingredient in Komboglyze, is a Biguanide; DPP‑4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults.

GNH USA supplies Komboglyze as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Komboglyze is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder that requires glycaemic control. - Type 2 diabetes mellitus: lowers blood glucose levels and improves HbA1c when used with diet and exercise. - Inadequate control on metformin alone: adds saxagliptin to achieve target glycaemic goals. - Adjunct to lifestyle modification: supports diet and exercise in managing type 2 diabetes.

Komboglyze may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools. - Headache: transient cranial discomfort. - Upper respiratory tract infection: mild cold‑like symptoms. - Abdominal pain: intermittent discomfort. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Hepatic failure: signs of liver dysfunction. - Hypoglycaemia (when combined with insulin or sulfonylureas): dizziness, sweating, confusion. - Renal impairment: worsening kidney function.

Before initiating Komboglyze, clinicians should evaluate patient-specific risk factors and monitor relevant clinical parameters. - Renal function assessment: avoid in severe renal impairment. - Hepatic function monitoring: use caution in patients with liver disease. - Lactic acidosis risk: discontinue if signs of metabolic acidosis appear. - Hypoglycaemia potential: monitor when combined with insulin or sulfonylureas. - Pregnancy and lactation: assess risk‑benefit, as safety data are limited. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Komboglyze can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate lactic acidosis in patients with renal dysfunction. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase saxagliptin exposure. - Insulin secretagogues (e.g., sulfonylureas): heighten risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium. - Warfarin: occasional alteration of INR, require periodic monitoring. - Beta‑blockers: may mask hypoglycaemia symptoms. - Alcohol: can potentiate metformin‑related lactic acidosis.